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Summary According to literature, approximately 20%-70% of patients 
sensitized to pollen allergens experience oral allergy syndrome (OAS) 
symptoms after eating raw fruits and vegetables. There is no standard 
treatment established for OAS except avoiding implicated food. However, 
in patients with airborne pollen allergy treated with specific immunotherapy 
(SIT), an improvement of OAS symptoms has been reported in 30% to 
even 84% of individuals examined. The aim of the present study was 
to evaluate the prevalence of OAS symptoms in patients with various 
manifestations of pollen airborne allergy (atopic dermatitis (AD), asthma, 
allergic rhinitis) treated with subcutaneous type of SIT. In addition, the 
most common patterns of cross-reactivity in OAS were analyzed and 
correlations between OAS symptoms and patient age, type of sensitizing 
pollen allergens and atopy manifestations investigated. Also, the 
relationship between SIT duration and clinical improvement of both OAS 
symptoms and pollen allergy symptoms was analyzed. The study included 
57 patients with airborne allergy treated with allergen vaccination (60% 
male and 40% female). Allergic rhinitis was diagnosed in 71%, AD in 
19%, AD and asthma in 4%, allergic rhinitis and asthma in 4%, and both 
AD and allergic rhinitis in 2% of study patients. Twenty-eight percent of 
study patients complained of overt symptoms of OAS (22% of allergic 
rhinitis patients and 27% of AD patients); 69% of the subjects presenting 
with OAS showed polyvalent airborne allergy to pollens and 31% were 
sensitized to only one group of pollen allergens (mostly grass pollens, 
tree pollens and mugwort pollens). There was no statistically significant 
correlation between the presence of OAS symptoms and patient 
diagnosis, patient age and type of allergen vaccination used. According 
to patients’ opinion, SIT significantly improved oral symptoms in 50% of 
study patients, 44% reported no impact of SIT on OAS symptoms and 
6% of patients observed worsening of OAS symptoms after unintentional 
ingestion of implicated food during the course of SIT. The study revealed 
OAS as a significant problem in patients sensitized to various pollen 
allergens. The results on OAS prevalence in atopic subjects (28%) 
were consistent with some literature data. There was clear association 
between OAS and polyvalent airborne allergy (69%). Cross-reactivity 
patterns were typical (for example, tree pollen allergy – intolerance of 
apples, carrots and potatoes; grass pollen allergy – intolerance of kiwi 
fruit and tomatoes). Questionnaire analysis indicated that subcutaneous 
SIT significantly alleviated OAS symptoms associated with ingestion of 
the responsible fruit and vegetables in half of study subjects. Further 
evaluation of the duration/persistence and stability of the phenomenon 
is planned for the future.
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INTroduCTIoN
 According to early reports from 1948, “pa-
tients sensitive to catkin-bearing trees had incon-
veniences after eating hazelnuts, such as itch-
ing and burning in mouth and throat, and similar 
symptoms after eating raw apples and other kinds 
of fruits” (1). Indeed, it is currently well estab-
lished that patients suffering from pollinosis often 
present various adverse reactions after ingestion 
of certain plant-derived foods (2). Unpleasant 
symptoms (oral pruritus, edema of the lips and 
tongue, hoarseness) are usually restricted to oral 
mucosa and most frequently the term oral allergy 
syndrome (OAS) is used, although according to 
some authors it may be misleading (2), for in many 
cases ingestion of some fruits, vegetables and 
spices may also cause laryngeal edema, bronchi-
al asthma and severe gastrointestinal symptoms. 
Thus, the term pollen-food syndrome (PFS) has 
also been proposed and is by many considered 
more appropriate (3). The most common and well 
described PFSs or OASs include birch-fruit syn-
drome, celery-mugwort-spice syndrome and rag-
weed-melon-banana syndrome (2,4).
 There is no standard treatment established for 
OAS except avoiding implicated food. However, 
it has been observed that approximately 50% of 
patients with airborne pollen allergy treated with 
specific immunotherapy (SIT) experience im-
provement of OAS symptoms (5-8). Therefore, it 
seems that SIT with pollen allergens may have a 
beneficial effect on OAS (4).
 The aim of the present study was to evaluate 
the prevalence of OAS symptoms in patients with 
various manifestations of pollen airborne allergy 
(atopic dermatitis (AD), asthma, allergic rhinitis) 
treated with subcutaneous type of SIT. We also 
analyzed the most common patterns of cross-re-
activity in OAS and investigated the association 
between OAS and patient age, type of sensitiz-
ing pollen allergens and atopy manifestations. 
Furthermore, relations between SIT duration and 
clinical improvement of both OAS symptoms and 
pollen allergy symptoms were analyzed.
PaTIeNTS aNd meThodS
 The study included a group of 57 patients (23 
female and 34 male), mean age 26.6±9.9, range 
8-53 years. All subjects presented various mani-
festations of airborne allergy; the diagnosis of al-
lergic rhinitis was made in 71%, AD in 19%, AD and 
asthma in 4%, allergic rhinitis and asthma in 4%, 
and AD and allergic rhinitis in 2% of study patients. 
All patients were treated with perennial SIT using 
depot aluminum hydroxide-adsorbed airborne al-
lergen extracts (Novo Helisen Depot-NHD, Nexter 
Allergopharma) (Table 1). The mean duration of 
SIT was 2.7±1.7, range 1-6 years. A short ques-
tionnaire was used to get information on a wide 
variety of OAS symptoms in each atopic individ-
ual, together with a list of culprit fruits and veg-
etables. Moreover, patients complaining of OAS 
were asked about their opinion about the possible 
SIT effect on their oral symptoms (no effect, alle-
viation of OAS symptoms, complete resolution of 
OAS, or exacerbation of OAS symptoms), and to 
evaluate SIT general efficacy (improvement, com-
plete remission, no effect or exacerbation of atopic 
dermatitis, allergic rhinitis or asthma).
Table 1. An overview of allergen vaccines used in atopic patients
Allergen vaccine type Number of patients
Novo Helisen Depot – grasses 100% 28
Novo Helisen Depot – grasses 80%, mugwort 20% 13
Novo Helisen Depot – grasses 80%, birch 20% 1
Novo Helisen Depot – mugwort 100% 3
Novo Helisen Depot – birch 35%, alder 30%, hazel 35% 8
Allergovit – grasses 100% 3
Allergovit – grasses 80%, mugwort 20% 1
Figure 1. Symptoms present after ingestion of 
certain foods in patients suffering from PFS.
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 Sixteen (28%) atopic patients complained 
of clear OAS, or rather PFS symptoms (Fig. 1). 
Among OAS-positive patients, three suffered from 
AD, one patient had both AD and asthma, another 
one suffered from AD and allergic rhinitis, nine 
had isolated symptoms of allergic rhinitis, and two 
patients had allergic rhinitis and asthma. Further-
more, among individuals presenting with OAS, 
11 (69%) had polyvalent airborne allergy to pol-
lens and five (31%) were sensitized to only one 
group of pollen allergens (predominantly grass, 
tree and mugwort pollen allergens). Most of the 
patients presenting OAS symptoms were treated 
with Novo Helisen Depot allergy vaccines com-
posed of tree and grass pollen allergens (Fig. 2). 
In the same group of patients, the cross-reactivity 
patterns between pollen and food allergens were 
typical (Table 2). 
 There was no statistically significant correlation 
between the presence of OAS symptoms and 
patient age, diagnosis and type of allergen vac-
cination used. According to the patients’ opinion, 
SIT significantly improved OAS symptoms in eight 
(50%) of 16 subjects; seven of 16 (44%) subjects 
reported no clear impact of SIT on OAS symp-
toms, and one (6%) patient observed worsening 
of OAS symptoms after unintentional ingestion of 
implicated food during the course of SIT (Fig. 3).
Figure 2. Composition of allergy vaccines in pa-
tients presenting OAS symptoms
Table 2. Most common cross-reactivity patterns between pollen and food allergens observed in study 
patients presenting oral allergy syndrome symptoms
Type of sensitizing airborne allergens Cross-reacting foods/spices Number of patients
Patients allergic to: 
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 Consecutive analysis concerned overall impact 
of SIT on disease severity in allergic rhinitis, AD and 
asthma (presented inTable 3). Among patients suf-
fering from allergic rhinitis, three patients achieved 
asymptomatic status, four patients observed im-
provement, whereas in two patients there was no 
impact of SIT on disease severity. Complete re-
mission was observed in one AD patient, whereas 
in two patients SIT led to improvement. According 
to the opinion of two patients presenting the symp-
toms of allergic rhinitis and asthma, the symptoms 
of asthma improved in both patients and those of 
allergic rhinitis in one patient, whereas the other 
Table 3. Impact of specific immunotherapy (SIT) on both oral allergy syndrome (OAS) symptoms and 
disease severity in 16 study patients
Patient 
No.









1 19/F Novo Helisen Depot
grasses 80%, birch 20%
12 A AR – B
2 32/M Novo Helisen Depot
grasses 80%, mugwort 20%
12 B AD – A 
3 27/F Novo Helisen Depot
grasses 80%, mugwort 20%
12 C AD – D
AR – B
4 30/M Novo Helisen Depot
birch 35%, alder 30%, hazel 35%
24 B AR – C
5 26/F Novo Helisen Depot
mugwort 100%
36 A AR – A
6 30/M Allergovit
grasses 100%
36 A AR – A
7 23/M Novo Helisen Depot
grasses 80%, mugwort 20%
12 A AR – C
As – B
8 13/M Novo Helisen Depot
grasses 100%
48 B AR – B 
As – B
9 32/M Novo Helisen Depot
birch 35%, alder 30%, hazel 35%
12 B AD – B
10 22/F Novo Helisen Depot
grasses 100%
12 B AD – B
As – B
11 25/M Novo Helisen Depot
grasses 100%
60 A AR – B
12 11/F Novo Helisen Depot
birch 35%, alder 30%, hazel 35%
36 A AD – B
13 53/M Novo Helisen Depot
birch 35%, alder 30%, hazel 35%
48 A AR – A
14 16/M Novo Helisen Depot
birch 35%, alder 30%, hazel 35%
6 B AR – C
15 31/F Novo Helisen Depot
grasses 100%
36 B AR – B
16 29/M Novo Helisen Depot
grasses 100%
36 A AR – B
*A = clear improvement of OAS symptoms; B = no impact of SIT on OAS symptoms; C = worsening of OAS symp-
toms
**AD (atopic dermatitis): A = asymptomatic status; B = improvement; C = no impact of SIT on disease symptoms; 
D = exacerbation of the disease
AR (allergic rhinitis): A = asymptomatic status; B = improvement; C = no impact of SIT on disease symptoms; 
D = exacerbation of the disease
As (asthma): A = asymptomatic status; B = improvement; C = no impact of SIT on disease symptoms; D = exacerba-
tion of the disease
Figure 3. Effect of SIT on OAS symptoms  
according to patients’ opinion.
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one observed no significant effect of SIT on the 
severity of allergic rhinitis. In one patient present-
ing AD and asthma, improvement occurred in both 
diseases, whereas only one patient with AD and 
allergic rhinitis reported exacerbation of AD along 
with improvement of allergic rhinitis.
dISCuSSIoN
 According to several authors, from 23% to 
even 70% of individuals diagnosed with pollen al-
lergy experience symptoms referred to as OAS 
after ingestion of raw fruits and vegetables, as a 
consequence of cross-reactivity between pollen 
and food allergens (9-12). Reactions to certain 
foods are often confined to oral itching or burn-
ing sensation, but may also involve more severe 
systemic reactions (2). In the present study, the 
overall prevalence of OAS in atopic patients was 
28% (which is consistent with literature data), and 
predominantly affected individuals suffering from 
allergic rhinitis (over 56%) and patients present-
ing polyvalent allergy to various airborne pol-
len allergens (69%). It is worth emphasizing that 
apart from complaints restricted to oral mucosa 
(oral pruritus, edema, burning), several patients 
presented symptoms originating from respiratory 
and alimentary system (dyspnea, abdominal pain, 
nausea, diarrhea, sneezing). Therefore, in ac-
cordance with some authors’ opinion mentioned 
above (2,3), the term PFS, or pollen-food allergy 
syndrome may be more precise and appropriate.
 In respect to the cross-reactivity pattern, apple 
is definitely considered as the most commonly in-
volved food, probably due to the high homology 
between its major allergen (Mal d 1) and major 
birch pollen allergen (Bet v 1) (5). Specific IgE 
against apple is detectable in sera of almost all 
birch pollen-sensitive patients (13). In our study, 
stone fruits (apple, pear, plum and peach) pre-
dominated in the cross-reactivity pattern, espe-
cially in patients with polyvalent airborne allergy 
to grasses, trees and weeds but also to grasses 
and mugwort, and in individuals with monovalent 
allergy to tree pollen allergens. Less common but 
noteworthy would be the cross-reactivity pattern 
observed in two of our patients allergic to mugwort 
and to both mugwort and grass pollen allergens 
and presenting OAS symptoms after ingestion 
of peas. Recently, Figueroa et al. (14) have pro-
posed a novel mustard-mugwort allergy syndrome 
to describe associations with mugwort pollinosis 
and several botanically unrelated plant-derived 
foods, especially nuts and legumes. The possible 
causative allergens include Art v 60 kDa, Art v 4 
(profilin) and Art v 3, a mugwort nonspecific lipid 
transfer protein (LTP).
 SIT is an established method of treatment in 
pollen allergy (presenting as allergic rhinitis, asth-
ma or AD), influencing the natural course of aller-
gic inflammatory process (4,15,16). Since OAS, or 
PFS is associated with cross-reactivity of certain 
allergens, SIT may lead to resolution not only of 
allergic rhinitis or AD but also of the associated 
food intolerance (2). According to early reports by 
Möller (7) in 72 children with severe rhinoconjunc-
tivitis due to birch pollinosis, hay fever symptoms 
improved by SIT but neither subcutaneous (n=42) 
nor oral (n=14) immunotherapy with birch pollen 
allergen preparations made the food sensitiv-
ity decrease significantly more than the placebo 
oral immunotherapy (n=16). Kelso et al. (6) have 
described a patient with allergic rhinitis and oral 
allergy syndrome in which the disease symptoms 
resolved after one year of SIT, and he was able to 
eat fresh fruits and vegetables without any reac-
tion. Skin testing and specific IgE immunoassay 
demonstrated marked reduction in sensitivity not 
only to pollen allergens but to foods as well. In the 
authors’ opinion, these results support the con-
cept that OAS is due to cross-reacting allergens 
in foods and pollens and may be amenable to 
treatment with SIT. Subsequent open apple chal-
lenge in a placebo-controlled prospective study 
performed by Asero (5) demonstrated significant 
reduction or complete disappearance of OAS 
symptoms in 84% of individuals monosensitized 
to birch pollen allergens, suggesting a beneficial 
effect of SIT on the food-pollen allergy syndrome. 
On the other hand, according to Bucher et al. (4), 
in spite of the favorable impact of OAS to apple 
or hazelnut in birch pollen-allergic individuals, the 
amount of fruit tolerated is still very small and thus 
the effect of SIT on the patients’ management of 
OAS remains limited. 
 In the present study, 50% of patients observed 
clearly a beneficial effect of SIT on OAS. Almost all 
of these patients suffered from allergic rhinitis (7 of 
8) and most of them also observed either improve-
ment of the primary airborne allergy symptoms or 
even were in asymptomatic status in the course 
of SIT. However, 44% of study patients reported 
no impact of SIT on their food-related complaints, 
while most of them still noted improvement of their 
airborne allergy symptoms. Therefore, the advan-
tage of SIT in OAS still remains controversial and 
needs to be further evaluated. Only one patient 
(a 27-year-old female) reported exacerbation of 
both OAS symptoms and AD symptoms during 12 
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months of SIT with grass and mugwort pollen ex-
tracts, but unfortunately in this case we observed 
both the lack of compliance and reluctance to-
wards SIT.
 Undoubtedly, an interesting issue for the future, 
also in case of the group of patients analyzed in 
the present study, would be evaluation of long-
term efficacy of SIT with pollen extracts on the 
pollen-related food syndrome. According to a re-
cent study by Asero (12), at least in some patients 
pollen SIT can exert a long-lasting effect on pol-
len-associated food allergies (patients sensitized 
to birch pollen were still able to eat apples without 
any complaints as long as 30 months after the end 
of SIT). However, the study was carried out in a se-
lected population characterized by total remission 
of clinical symptoms and skin reactivity to apple 
at the end of SIT course, and these results might 
not be valid for the whole population. Moreover, in 
many cases apple intolerance showed a tendency 
to recur upon SIT discontinuation, probably due to 
prolonged and repeated exposure to the primary 
sensitizing allergen (birch pollen).  
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